Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Designed to be modular and flexible, it will accommodate multiple product types within rare diseases, such as hemophilia. Construction work has commenced and is scheduled to be completed in 2027.On Monday, Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion Danish kroner) to establish a new production facility in Odense, Denmark.
週一，丹麥藥品公司諾和諾德A/S（紐交所：NVO）宣佈計劃投資約12億美金（85億丹麥克朗）在丹麥奧登塞建立一個新的生產設施。
The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site. The new site will feature a finished production facility and warehouse of over 40,000 m2.
此項投資標誌着諾和諾德在本世紀首次在丹麥開工建立新的生產基地。新基地將設有超過40,000平方米的成品生產設施和倉庫。
Also Read: Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study
另請閱讀：諾和諾德的Ozempic可能與罕見視力喪失風險相關，但絕對風險很低：研究
Designed to be modular and flexible, it will accommodate multiple product types within rare diseases, such as hemophilia. Construction work has commenced and is scheduled to be completed in 2027.
該設施設計爲模塊化和靈活，將容納多種罕見疾病產品類型，例如血友病。施工工作已經開始，定於2027年完成。
The investment is expected to create 400 permanent jobs upon completion of the facilities. Up to 1,000 external employees will be working on-site during the construction process.
預計這筆投資將在設施完成後創造400個永久性工作崗位。在施工過程中，將有多達1,000名外部員工在現場工作。
On Friday, Novo Holdings announced it had fulfilled all regulatory requirements to finalize its acquisition of Catalent Inc. (NYSE:CTLT).
週五，諾和控股宣佈已滿足所有監管要求，以完成對Catalent Inc.（紐交所：CTLT）的收購。
The closure comes amid a coalition of unions, consumer groups, and public interest organizations voicing strong opposition to Novo Holdings' proposed $16.5 billion acquisition of Catalent.
此次收購引發了一 coalition of unions, consumer groups, and public interest organizations 對諾和控股提議的165億美金收購Catalent的強烈反對。
Last week, the European Commission approved Novo Holdings' acquisition of Catalent and Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings.
上週，歐洲委員會批准了諾和控股對Catalent的收購及諾和諾德隨後從諾和控股收購三個製造基地。
The deal for the three sites is expected to close in the coming days. Once completed, the acquisition will affect Novo Nordisk's financial outlook, including:
這三個地點的交易預計將在接下來的幾天內完成。一旦完成，該收購將影響諾和諾德的財務前景，包括：
2024 Impact: A slight negative effect on operating profit growth and a reduction in free cash flow by $11.7 billion, the acquisition's cost. The ongoing 20 billion Danish krone share buyback program remains unaffected.
2024年影響：對營業利潤增長略有負面影響，自由現金流減少117億萬億。收購成本的股權回購計劃200億丹麥克朗不會受到影響。
2025 Impact: Operating profit growth is projected to face a moderate negative impact, with interest payments from debt financing affecting net financial items. Novo Nordisk does not plan to launch a share buyback program in 2025.
2025年影響：營業利潤增長預計將面臨中等負面影響，債務融資的利息支付將影響淨財務項目。諾和諾德計劃在2025年不發起股票回購計劃。
Price Action: At last check on Monday, NVO stock was up 0.93% at $107.94 during the premarket session.
價格動態：在週一最後檢查時，NVO股票在盤前交易中上漲了0.93%，成交價爲107.94美元。
- Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
- 儘管估值較高，一些生命科學工具類股票仍然創造了良好的機會：分析師
Photo via Shutterstock
圖片來自shutterstock
譯文內容由第三人軟體翻譯。
